G-dase E

G-dase E is a novel, RNA-guided nuclease-based technology developed for programmable cell depletion. It belongs to a new family of CRISPR nucleases with a unique mechanism of action. Unlike traditional CRISPR systems that edit DNA by introducing double-stranded breaks, G-dase E is activated upon binding to specific intracellular RNA biomarkers via a programmable guide RNA. Once activated, it enters a collateral cleavage mode that shreds all types of nucleic acids within the targeted cell—preferentially double-stranded DNA—leading to rapid and selective cell death without editing or mutating the genome. This approach enables highly specific depletion of cells expressing particular RNA markers and holds promise for applications in precision oncology (notably HPV-induced oropharyngeal head & neck cancer), autoimmune diseases, fibrosis, infectious diseases, and more[3][5][8]. The technology is being advanced by Akribion Therapeutics GmbH.